Interim report January-March 2008

Interim report January-March 2008

Strong sales and income growth

• Sales increased by 19 percent to SEK 58.7 (49.2) million. Calculated in local
sales currencies growth was 20 percent. 

• Gross income increased by 20 percent to SEK 40.5 (33.8) million, the gross
margin was 69 percent (69). 

• Operating income increased by 33 percent and amounted to SEK 10.6 (8.0)
million, which gives an operating margin of 18 (16) percent.

• Operating income before research and development costs increased by 25 percent
to SEK 18.3 (14.6) million. This corresponds to a margin of 31 (30) percent.

• Consolidated net income was SEK 8.1 (11.0) million, which gives earnings per
share of SEK 0.41 (0.55). However, last year's figure includes capitalization of
the deferred tax asset in loss carry-forward for tax purposes to the tune of SEK
4.1 million. Adjusted for this item net income increased by 18 percent.

• The cash flow from operating activities amounted to SEK 6.7 (5.0) million, an
increase of 34 percent.

• The equity/assets ratio amounted to 84 percent (82).

• Acquisition of majority shareholding in Italian distributor. 

• Start of direct marketing of all fertility products in France announced.

• Products for the cold storage of embryos approved in Canada and in Europe. 

• IVF products approved in Russia.


April 28, 2008
Kungsbacka, Sweden 

Magnus Nilsson
CEO


Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share
is listed on the OMX Nordic Exchange's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

The information in this press release is such as that which Vitrolife is
required to publish in accordance with the Securities Exchange and Clearing
Operations Act.

This is a translation of the Swedish version of the interim report. When in
doubt, the Swedish wording prevails.